Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Immunotherapy with bestatin for acute nonlymphocytic leukemia in adults

  • 28 Accesses

  • 32 Citations

Summary

In a cooperative randomized control study of immunotherapy with bestatin in combination with chemotherapy in adults with acute nonlymphocytic leukemia (ANLL), 101 patients (48 in the bestatin group and 53 in the control group) out of 115 patients registered were evaluated as eligible. The bestatin group achieved a statistically significant prolongation of survival compared with the control group in overall ANLL and acute myelogenous leukemia. In the analysis of patient age, the bestatin group achieved a statistically significant prolongation of both the remission duration and survival in patients aged 50 to 65 years, while the differences were not significant in the 15 to 49 age group. The bestatin group tended to achieve a higher rate of reinduction of remission in patients who had recurrence of leukemia. Side effects developed in only 5 (9.6%) of 52 patients treated with bestatin. None of these side effects were particularly serious in nature. It is concluded that bestatin is useful for prolongation of survival of adult patients with ANLL, making for a longer remission duration especially in elderly patients and with few side effects.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Brandman J, Bulowski RM, Greenstreet R et al (1979) Prognostic factors affecting remission, remission duration, and survival in adult acute nonlymphocytic leukemia. Cancer 44:1062–1065

  2. 2.

    Bruley-Rosset M, Frorentin I, Mathé G et al (1979) Resoration of impaired immune functions of aged animals by chronic bestatin treatment. Immunology 38:75–83

  3. 3.

    Foon KA, Smalley RV, Riggs CW et al (1983) The role of immunotherapy in acute myelogenous leukemia. Arch Intern Med 143:1726–1731

  4. 4.

    Ishizuka M, Masuda T, Kanbayashi N et al (1980) Effect of bestatin on mouse immune system and experimental murine tumors. J Antibiot 33:642–652

  5. 5.

    Majima H, Suzuki M, Nakano M (1980) Clinical experience of bestatin-preliminary report. Jpn J Cancer Chemother 7 (1):89–94

  6. 6.

    Mertelsmann R, Thaler HT, To L et al (1980) Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood 56:773–781

  7. 7.

    Nakamura H, Masaoka T, Ohno R et al (1983) Immunotherapy with Nocardia rubra cell-wall skeleton for acute myelogenous leukemia adult. Acta Haematol (Jpn) 46:1087–92

  8. 8.

    Powles RL, Russell J, Lister TA et al (1977) Immunotherapy for acute myelogenous leukemia: A controlled clinical study \(2{\raise0.5ex\hbox{$\scriptstyle 1$}\kern-0.1em/\kern-0.15em\lower0.25ex\hbox{$\scriptstyle 2$}}\) years after entry of the last patient. Br J Cancer 35:265–272

  9. 9.

    Saito K, Miyasato H, Ikeda S et al (1983) Phase I study of bestatin (1) A clinical study on determination of an optimal dose of bestatin. Jpn J Cancer Chemother 10 (2) PART I:211–217

  10. 10.

    Umezawa H, Aoyagi T, Suda H et al. (1976) Bestain, an inhibitor of aminopeptidase B, produced by actinomycetes. J Antibiot 29:97–99

  11. 11.

    Yamada K (1984) Chemotherapy of acute myelogenus leukemia. Igaku no ayumi 128:994–998

  12. 12.

    Yamada K, Kawashima K, Morishima Y et al (1978) Chemoimmunotherapy of acute myelogenous leukemia in adults with BCG cell-wall skeleton. Gann 21:199–209

  13. 13.

    Yamada K, Suzuki H, Kato Y (1980) Phase III study of N4-behenoyl-1-β-D-arabinofuranosylcytosine in adult acute leukemia-BHAC·DMP therapy. Acta Haematol (Jpn) 43:1080–1085

Download references

Author information

Correspondence to Kazuo Ota.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ota, K., Kurita, S., Yamada, K. et al. Immunotherapy with bestatin for acute nonlymphocytic leukemia in adults. Cancer Immunol Immunother 23, 5–10 (1986). https://doi.org/10.1007/BF00205548

Download citation

Keywords

  • Leukemia
  • Elderly Patient
  • Cancer Research
  • Adult Patient
  • Myelogenous Leukemia